By |

Profile

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).

Contact Information

Website: www.amgen.com
Email: investor.relations@amgen.com
Main Phone: +1 805 447-1000
Address: One Amgen Center Drive
Address 2: Suite 2650
State: CA
City / Town: Thousand Oaks
Country: USA
Postal Code: 91320-1799

Issuer Information

Exchange: NGS
CEO: Robert A. Bradway
Employees: 23400
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More

Profile

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).

Contact Information

Website: www.amgen.com
Email: investor.relations@amgen.com
Main Phone: +1 805 447-1000
Address: One Amgen Center Drive
Address 2: Suite 2650
State: CA
City / Town: Thousand Oaks
Country: USA
Postal Code: 91320-1799

Issuer Information

Exchange: NGS
CEO: Robert A. Bradway
Employees: 23400
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

View More
$ 258.24 $ 3.12 (1.22%)
Last Price 258.24 Change $ 3.12 Change % 1.22 Tick N/A
Bid 258.99 Bid Size 300.00 Ask 261.49 Ask Size 100.00
Open 252.87 High 261.46 Low 252.87 Prev Close 255.12
Last Trade Volume 3.3 mi 52 Wk Hi 261.46 52 Wk Low 173.12
Market Cap 151.9 bi Ex-Div Date Div Rate 6.40 Yield 2.4780
Shares 588,247,399.00 EPS (TTM) 12.78 PE Ratio 20.20 Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 45 74
Number of Buys 23 31
Number of Sells 22 43
Net Activity -8304 75103
Last 10 Buys Shares
Fred Hassan 1,000
Fred Hassan 1,000
Frank C. Herringer 1,000
Frank C. Herringer 1,000
Robert A. Bradway 1,000
Last 10 Sell Shares
Sean Harper 1,000
Sean Harper 1,000
Sean Harper 1,000
Sean Harper 1,000
Sean Harper 1,000
Sean Harper 1,000
Sean Harper 1,000
Sean Harper 1,000
De Francois Carbonnel 1,000
Sean Harper 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 224 224 224 224
Low Target Price Estimate 165 165 165 165
Mean Target Price Estimate 193.94 193.94 193.12 193.94
Standard Deviation 15.01 15.01 14.92 15.01
Date of Most Recent Estimate 06/03/18 05/22/18 05/22/18 06/03/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 7 7 7 7
Moderate Buy 1 1 1 1
Hold 12 13 14 14
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.22 2.26 2.3 2.3